Best Research Peptides 2026: Most-Studied, Ranked
An evidence-tier overview of the research peptides in our catalogue that appear most often in the published scientific literature. For each compound you will find what it is, which research areas the literature covers, and links to the product page and to our batch lab reports. Every compound listed is supplied strictly for in-vitro laboratory research.
How this ranking works
The tiers reflect the published evidence base, not a recommendation. Three criteria decide where a compound sits:
- Publication volume - how much peer-reviewed literature exists on the compound, from cell, animal and mechanistic studies.
- Mechanistic clarity - whether the receptor or pathway the compound acts on has been characterised.
- Independent replication - whether key findings have been reproduced by laboratories other than the originating group.
Tier S - most extensively published
Compounds with the largest body of replicated preclinical literature and the most consistent mechanistic picture.
BPC-157
A synthetic 15-amino-acid peptide derived from a sequence found in a gastric protein. It is one of the most published research peptides, studied mainly in rodent models of tendon, gastrointestinal and vascular injury. Proposed mechanisms in the literature involve nitric-oxide signalling and VEGFR2-mediated angiogenesis pathways.
TB-500 (Thymosin Beta-4 fragment)
A synthetic peptide based on the actin-binding region of thymosin beta-4, an abundant intracellular protein. Research centres on its LKKTETQ motif, which binds G-actin and influences cytoskeletal organisation and cell migration in vitro. Animal studies have examined it in models of skin, cardiac and nerve injury.
GHK-Cu
A naturally occurring copper-binding tripeptide (glycyl-histidyl-lysine) first identified in human plasma. Cell-culture studies examine its effects on gene expression, extracellular-matrix synthesis and antioxidant pathways in fibroblasts and other cell types. It is also widely used as a reference compound in copper-peptide chemistry.
Ipamorelin
A synthetic pentapeptide that acts as a selective agonist of the ghrelin receptor (GHSR1a). In animal pharmacology studies it stimulates growth-hormone release with little effect on cortisol or prolactin, which makes it a reference tool for receptor-selectivity research. It is frequently studied alongside GHRH analogues such as CJC-1295 and tesamorelin.
Tier A - strong mechanism, growing literature
Active research areas with a well-characterised mechanism but a smaller or more recent evidence base than Tier S.
Retatrutide
An investigational single peptide that acts on three receptors: GLP-1, GIP and glucagon. It is a current focus of incretin and receptor-pharmacology research, where the question is how combined receptor activation differs from single-receptor agonists. It has no marketing authorisation as a medicine in the EU.
Tesamorelin
A synthetic analogue of growth-hormone-releasing hormone (GHRH 1-44), stabilised with a trans-3-hexenoyl group. It is used in research on GHRH receptor pharmacology and the growth-hormone axis. A medicinal formulation is authorised outside the EU; the product we supply is a research reagent only.
MOTS-c
A 16-amino-acid peptide encoded within the 12S rRNA region of mitochondrial DNA. Cell and rodent studies examine its role in AMPK signalling, glucose metabolism and the cellular response to metabolic stress. It is a reference compound in the emerging field of mitochondrial-derived peptides.
Epithalon
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied in ageing research. Published work reports effects on telomerase activity in cultured cells and on lifespan endpoints in rodents, largely from a single research group. Independent replication is still limited, which is why it sits in this tier rather than above.
5-Amino-1MQ
A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide, used as a probe in metabolic cell biology. Studies in adipocyte cell lines and rodents examine the role of NNMT in cellular energy metabolism and NAD+ salvage. It is a research tool rather than a clinical candidate.
Tier B - emerging, less replicated
Compounds with a clear receptor or pathway hypothesis and interesting preclinical signals, but a smaller literature and less independent replication.
KPV
A tripeptide (Lys-Pro-Val) corresponding to the C-terminal end of alpha-melanocyte-stimulating hormone. It is studied in in-vitro and rodent models of intestinal and skin inflammation, with research focused on NF-κB signalling. The published literature is still small.
VIP
Vasoactive intestinal peptide, a 28-amino-acid neuropeptide that acts on the VPAC1 and VPAC2 receptors. It is used as a pharmacology tool in neuroscience, immunology and vascular research. Its short half-life in biological systems is itself a frequent subject of study.
NAD+
Nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. It is a core reagent in research on energy metabolism, sirtuins and PARP enzymes, and in cell and animal models of ageing. Strictly speaking it is a nucleotide, not a peptide.
Thymosin Alpha-1
A 28-amino-acid peptide originally isolated from thymus tissue. It is studied in immunology, mainly for its effects on T-cell maturation and innate immune signalling in cell and animal models. Medicinal formulations exist in some countries outside the EU; the product we supply is a research reagent only.
AOD9604
A modified fragment of human growth hormone (amino acids 177-191). It is used as a research tool in studies of lipid metabolism in adipocyte cultures and rodents. It does not share the receptor-binding profile of growth hormone, which is part of its research interest.
Tier C - niche, strict RUO caveat
Compounds with a sparse modern literature or known safety concerns outside the laboratory. They are listed for transparency because we supply them, and they belong strictly in controlled in-vitro work.
Melanotan-2
A synthetic cyclic analogue of alpha-MSH that activates several melanocortin receptors. Its relevance today is as a tool in melanocortin receptor pharmacology. Unregulated use outside the laboratory has been linked to published safety reports, and it is supplied for in-vitro research only.
PT-141 (Bremelanotide)
Bremelanotide, a cyclic peptide that acts mainly on the melanocortin-4 receptor. It is used in research on central melanocortin signalling. A medicinal formulation is authorised in the United States; the product we supply is a research reagent only.
DSIP
Delta sleep-inducing peptide, a nonapeptide first described in the 1970s. Early animal studies examined it in sleep regulation and neuroendocrine research, but the modern literature is sparse and its receptor has not been identified. It remains a legacy research tool.
Batch documentation and sourcing
Where a lot has been tested by an independent laboratory, the report is listed in our lab reports archive with its batch number, test date and the assays that were run. The assays differ from lot to lot, so check the report for the batch you receive. You can browse every compound in the shop, and the EU buying guide explains how research orders, shipping and invoicing work.
Frequently asked questions
Which peptide has the most published evidence in 2026?
Among peptides overall, semaglutide has the largest published literature, because it is an authorised medicine with an extensive clinical programme. It is not a research reagent and is not in our catalogue. Within this list, the Tier S compounds have the broadest preclinical literature.
Are these peptides legal to buy for research in the EU?
None of the compounds listed here has marketing authorisation as a medicine in the EU. They are sold as research reagents for in-vitro laboratory work only, not for human or veterinary use, and you are responsible for following the rules of your own country. Country notes are in our EU buying guide.
What does ‘third-party CoA’ mean and why does it matter?
A third-party Certificate of Analysis is issued by an independent testing laboratory rather than by the supplier. The laboratory has no stake in whether a result passes, which removes a bias an in-house test cannot avoid. Where we have one, you will find it in our lab reports archive and can match it to the batch number on the vial. Not every lot of every compound has a report yet.
Which of these peptides are prohibited by WADA in sport?
Many of them are on the World Anti-Doping Agency’s Prohibited List. Compounds with no regulatory approval, such as BPC-157, TB-500 and retatrutide, fall under S0 (non-approved substances); growth-hormone secretagogues and releasing factors such as ipamorelin and tesamorelin fall under S2. The list concerns anti-doping rules in sport; it does not change their status as laboratory reagents.
How often do you update this ranking?
We review the tiers periodically against new publications in PubMed, registrations on clinicaltrials.gov and changes to the WADA Prohibited List. The date at the bottom of this page shows the last review.
Research use only. All compounds on this page are supplied as research reagents for in-vitro laboratory work by qualified professionals. They are not medicines, they are not intended for human or veterinary use, and nothing on this page describes or recommends any use in humans or animals.
Last reviewed: 7 October 2026.